Frontiers in Pharmacology (Sep 2022)

Targeting non-coding RNA H19: A potential therapeutic approach in pulmonary diseases

  • Jinghui Xie,
  • Yuedi Hu,
  • Dengdi Sun,
  • Changan Liu,
  • Zegeng Li,
  • Zegeng Li,
  • Jie Zhu,
  • Jie Zhu,
  • Jie Zhu

DOI
https://doi.org/10.3389/fphar.2022.978151
Journal volume & issue
Vol. 13

Abstract

Read online

Non-coding RNA is still one of the most popular fields in biology research. In recent years, people paid more attention to the roles of H19 in lung diseases, which expressed abnormally in various pathological process. Therefore, this review focus on the regulatory role of H19 in asthma, pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF), lung injury, pneumonia, lung cancer, etc. And the potential therapeutic agents and molecular treatments of H19 are collected. The aim is to demonstrate its underlying mechanism in pulmonary diseases and to guide the basic research targeting H19 into clinical drug translation.

Keywords